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ABSTRACT
Purpose: Radiotherapy (RT) treatment of locally-advanced and recurrent head and neck carcinoma
(HNC) results in disappointing outcomes. Combination of RT with cisplatin or cetuximab improves sur-
vival but the increased toxicity and patient's comorbidity warrant the need for a less-toxic radiosensi-
tizer. Stimulated by several randomized studies demonstrating the radio-sensitizing effect of
hyperthermia, we developed the HYPERcollar. Here, we report early experience and toxicity in patients
with advanced HNC.
Methods and materials: 119 hyperthermia treatments given to 27 patients were analyzed.
Hyperthermia was applied once a week by the HYPERcollar aimed at achieving 39–43 C in the target
area, up to patients’ tolerance. Pre-treatment planning was used to optimize treatment settings. When
possible, invasive thermometry catheters were placed.
Results: Mean power applied during the 119 hyperthermia treatments ranged from 120 to 1007W
(median 543W). 15 (13%) hyperthermia treatments were not fully completed due to: pain allocated to
hyperthermia (6/15), dyspnea from sticky saliva associated with irradiation (2/15) and unknown reasons
(7/15). No severe complications or enhanced thermal or mucosal toxicities were observed. Excluding
post-operative treatment, response rates after 3months were 46% (complete) and 7% (partial).
Conclusion: Hyperthermia with the HYPERcollar proved to be safe and feasible with good compliance
and promising outcome.
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Introduction
Patients with locally advanced primary head and neck carcin-
oma (HNC) are usually treated with radiation therapy, often
combined with systemic therapy i.e., cisplatin or cetuximab.
However, combined treatment is not suitable for a propor-
tion of HNC patients. In patients with loco-regional treatment
only, a two-year loco-regional control rate of 50% and a two-
year overall survival rate of 53% was reported in a meta-ana-
lysis study by Pignon et al. [1]. In patients with loco-regional
radiation treatment combined with cisplatin or cetuximab, a
two-year loco-regional control rate of 53% for cetuximab and
80% for cisplatin; and a two-year overall survival rate of 68%
for cetuximab and 78% for cisplatin was reported [2].
For recurrent HNC, the treatment of choice is surgery or
(re)irradiation based on tumor site and previous irradiation.
However, only 20% of patients are fit for this treatment
and local tumor control after retreatment is only 26–52%
[3,4], leading to a two-year overall survival of 10–20% for
re-irradiation and chemotherapy [5]. Moreover, toxicity after
re-treatment with concurrent chemo-radiotherapy is substan-
tial (grade four toxicity 18–23% and grade five toxicity 5–8%)
[5,6]. Hence, treatment outcome in patients suffering from
locally advanced or recurrent HNC is insufficient. As most
patients die because of local recurrence or residual disease,
there is a need for improved loco-regional treatment [7].
Hyperthermia is known to enhance the therapeutic ratio of
radiation resistant tumors [8] and several randomized trials
demonstrated survival benefits by adding hyperthermia to
radiation [9–12]. In a systematic review and meta-analysis by
Datta et al. [13], a significant improvement in loco-regional
control (LRC) was found for HNC patients, with an odds ratio
of 2.92 (95% CI, 1.58–5.42) in favor of the combined treatment
of hyperthermia plus radiation versus radiation [14]. In a
phase III trial of Huilgol et al., hyperthermia-enhanced radi-
ation treatment resulted in a higher complete response
rate (79% versus 42% complete response) [15]. Given this abil-
ity of hyperthermia to enhance outcome without increasing
toxicity [16], it seems reasonable to further study the
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combination of radiotherapy with hyperthermia for HNC. The
development of the HYPERcollar has made it possible to
extend the application of hyperthermia from superficial to
deeply located HNC [17].
The aim of this study is to describe the early clinical
experience with deep hyperthermia treatment using the
HYPERcollar combined with radiotherapy. Hereto, we ana-
lyzed feasibility and toxicity of deep hyperthermia in a cohort
of patients with locally-advanced or recurrent HNC.
Patients and methods
Patients
Patients eligible for hyperthermia treatment were adults of
18 years and older, with a Karnofsky Performance Score
of70 and histologically proven HNC. We included consecu-
tive patients with either recurrence of HNC or patients with
inability to receive chemotherapy. Data were retrospect-
ively analyzed.
Exclusion criteria were systemic temperatures>39 C, oxy-
gen saturation<90%, claustrophobia, tumor caudally of a tra-
cheostoma (this prevents penetration of the microwaves to
the tumor) and the presence of a pacemaker.
Metal implants in the head and neck region were not a
contraindication. All work was conducted with the approval
of the local Medical Ethical Committee.
Radiotherapy
Radiotherapy was given using either external beam irradi-
ation or interstitial irradiation. A computerized tomography
(CT) scan was made while applying a patient-specific thermo-
plastic mask and intravenous contrast was injected for better
tumor visualization. Target volumes were delineated by the
HNC radiation-oncologist and used in both radiotherapy and
hyperthermia treatment planning.
Preferably, external beam irradiation was delivered stereo-
tactically using the Cyberknife (CBK) (Accuray Inc., Sunnyvale,
CA), because the higher dose per fraction is expected to lead
to a higher hyperthermia-induced enhancement. Intensity-
modulated radiotherapy (IMRT) was given in a 2Gy fraction
dose to a total dose of 40–70Gy, given 5 or 6 times a week
(19 patients). The 40Gy scheme was given with palliative
intent. Multiple fractionation schemes were used for the 7
patients treated with CBK (55.5 Gy, 65Gy, 65.5 Gy or
66Gy, given twice a week) [3,18,19]. For the interstitial
radiotherapy, a total dose of 38Gy in 12 fractions was given
(1 patient), dosed at 5mm depth. Brachytherapy (BT) and
CBK treatment was given to patients with recurrent disease
as a first re-treatment option; no elective nodal areas were
treated in these patients.
Hyperthermia
Hyperthermia was applied by radiofrequency (RF) electro-
magnetic energy using the HYPERcollar (Figure 1), a twelve
antenna applicator operating at 433MHz for target selective
heating [20]. Treatment planning was applied for each
patient to derive the settings per antenna (RF-power-weight-
ing, phase-difference) leading to an optimum heat focusing
at the target region. A full 3D patient model was generated
based on the planning CT for radiotherapy and comprised of
exterior, fat, muscle, bone, cartilage, white matter and grey
matter [20–22]. This 3D model was used for an electromag-
netic simulation per antenna. Next, the RF-power absorption
pattern, expressed in the specific absorption rate (SAR), was
optimized using the hotspot-target-quotient [22,23]. Target
coverage of 25% of the maximum SAR level (TC25%) [22]
was used to decide whether hyperthermia treatment was
deemed possible:
 TC25%  75%: hyperthermia was always applied.
 TC25% between 25 and 75%: inclusion depended on
feasibility of invasive temperature measurement.
 TC25%< 25%: hyperthermia was not applied.
Note that this criterion became more restrictive over time
since initially tumor properties were assigned to the entire
clinical target volume (CTV), leading to overestimated SAR in
non-tumor CTV regions. This was corrected when gross
tumor volume (GTV) delineations were introduced, which led
to lower SAR values in the CTV margin and hence substan-
tially lower TC25% values.
For thermometry purposes, closed-tip catheters were
placed in the tumor or in normal tissue, using preferably
local anesthesia, and/or at the skin (see Figure 2). A CT scan
was made to document the location of all catheter tracts.
Just before treatment, multi-sensors temperature probes
were inserted into the catheters for monitoring temperature
in the tumor or surrounding organs at risk. The exact inser-
tion length was measured for reconstructing the surrounding
tissue type for each sensor. The HYPERcollar was placed
around the target volume and the waterbolus was filled with
deionized water. This water was circulated at a temperature
of 20–30 C, depending on target depth. Pre-optimized RF-
power and phase settings were applied and RF-power was
gradually increased until target temperature or hotspots
were reached. Hyperthermia was applied for 60–75min
aimed at achieving 43 C throughout the target region, but
hotspots (normal tissue temperatures above 44 C or pain-
related discomfort) restricted this temperature. Initially, a
library of three to six SAR distributions were pre-optimized
for responding to hotspots [20]. Later, we introduced our
dedicated real-time complaint-adaptive treatment protocol
[20,22]. During treatment, we continuously monitored heart
rate, RF-power and phase per antenna, and temperature.
Evaluation
Over time, treatment time duration was increased from 60 to
75min, to account for the 15min heating-up phase, so toler-
ance was defined as the percentage of patients who com-
pleted 55min (60-min group) or 70min (75-min group).
The estimated SAR (SARest) [22] was calculated using the
real-time measured signals (power and phase) per channel
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Figure 1. Different views of the HYPERcollar, the clinical setup and an example simulated SAR pattern on top of a CT scan.
Figure 2. Example of intra-tumor thermometry catheters in the base of tongue.
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and the respective predicted electric field per antenna. An
experimentally defined applicator efficiency factor of 0.7 was
applied to account for losses in the conductors and antennas.
SARest was quantified by using the mean SARest in the target
region averaged over all sessions.
Measured temperatures were quantified using the time-
average of the T90 and T50, where T90 and T50 are the 90th
and 50th percentile of the temperatures measured at each
moment [24]. Three HNC hyperthermia groups were distin-
guished to stratify the analysis for location dependent differ-
ences in treatment quality 1) head central: consisting of nasal
cavity, paranasal sinus and nasopharynx; 2) head caudal: oral
cavity and oropharynx; 3) Neck: larynx, hypopharynx and
neck node metastases.
Follow-up and toxicity
Patients were weekly examined for the development of skin
or subcutaneous burns within 24 h after treatment. Since no
specific hyperthermia toxicity scoring system exists, toxicity
was assessed according to the generic Common Terminology
Criteria for Adverse Events (CTCAE) protocol, version 4.03
[25]. Assessment was based on data from patient’s records
and interviews, and responses were evaluated after
three months.
After treatment completion, patients were seen in the out-
patient clinic every 2months during the first year, every
3months for year 2, every 4months for year 3 and every
6months for years 4–5. Follow-up visits consisted of updat-
ing patient’s case history, physical examination and in case
of suspicion for recurrence, a CT or magnetic resonance
imaging (MRI) scan. Tumor response was analyzed by the
WHO guidelines [26] as complete, partial or no response.
Results
Patient statistics
Between February 2007 and July 2013, 27 patients were
treated with irradiation in combination with deep hyperther-
mia in HNC. The primary tumor was located in the orophar-
ynx [10], the larynx [5], the nasopharynx [5], the sinonasal
area [3], the oral cavity [3] and trachea [1]. Eighteen patients
were treated because of a recurrence and nine patients had
a locally advanced tumor. Three patients received post-opera-
tive RT (PORT), of these two had recurrent disease and one
locally advanced disease. Most patients (21/27) had squa-
mous cell carcinomas, three had adenoid cystic carcinoma,
one had mucoepidermoid lowgrade carcinoma and two
poorly differentiated non-keratotic carcinoma. All patients
had KPS>70, but did not receive concurrent chemo-radi-
ation. Chemotherapy was not added in 18/27 patients with
recurrent disease. In 9 patients with locally advanced disease
the reason to omit chemotherapy was: age (4/9 patients),
induction chemotherapy in stead of concurrent chemother-
apy (2/9), patient's refusal (1/9), palliative intent of treatment
(1/9) and unknown (1/9). Tumors had a median CTV size of
64ml (range 28–185ml).
The radiation dose ranged from BED 80 to 144Gy (median
BED 120Gy). For locally advanced disease, median BED was
128.3 Gy, for recurrent disease 116Gy. Table 1 shows the
demographics, tumor characteristics and treatment character-
istics of the patients.
Hyperthermia
In total, 119 hyperthermia treatments were given to the 27
patients, with a median of 4 treatments. Hyperthermia treat-
ments were given once or twice a week, 1–3 h after
irradiation.
The median duration of hyperthermia was 60min (range
18–75min). Catheters for thermometry were placed in 16
patients, for measuring temperatures in the tumor (8/16) or
organs at risk (8/16). Due to a strong confounding influence
of swallowing and speaking, we abandoned intraluminal tem-
perature measurements after the first two patients.
Median SARest for the whole group was 72.6W/kg, which
increased over time from 60.7W/kg (60-min group) to
81.8W/kg (75-min group). The increase in applied power by
21% (464W to 595W) led to an even higher increase of
SARest of 35% (60.7W/kg to 81.8W/kg), indicating an
improvement of the applied SAR pattern by the new steer-
ing method.
The median measured temperature in the tumor or
normal tissue per patient was 38.8 C (range 37.8–39.3 C)
(Table 2). Note that temperatures were measured predomin-
antly in challenging cases since invasive thermometry was
mandatory in our protocol when the predicted TC25% was
below 75%.
Table 1. Patient, tumor and treatment characteristics.
Total 27
Sex (n (%))
Males 17 (63)
Females 10 (37)
Age (median (range))
Total 60 (17–85)
Males 60 (17–85)
Females 61 (38–81)
Prior chemotherapy (n (%)) 5 (18)
Prior surgery (n (%)) 3 (11)
Indications (n (%))
Locally advanced 9 (33)
Re-irradiation 18 (67)
Tumorsite
Head central (n (%))
Sinonasal 3 (11)
Nasopharynx 5 (19)
Head caudal (n (%))
Oral cavity 3 (11)
Oropharynx 10 (37)
Neck (n (%))
Larynx 5 (19)
Trachea 1 (4)
RT technique (n (%))
IMRT 19 (70)
CBK 7 (26)
BT 1 (4)
BT: brachytherapy; CBK: Cyberknife; IMRT: intensity-
modulated radiotherapy.
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Toxicity and early experience
Only 2 patients experienced grade 2 toxicity due to hyper-
thermia treatment, both of them were treated for a sinonasal
carcinoma near the eye. This toxicity, a burning sensation of
the eyeball, existed before treatment in one of these patients
but increased.
Mean hyperthermia treatment time was 94% of planned
duration. 15/119 (13%) hyperthermia treatments were
stopped before the prescribed duration: Nine treatments in
the 60-min group and six in the 75-min group. Six treatments
were stopped due to additional pain caused by the tumor or
treatment position, which we allocated to hyperthermia. In
two cases treatment was interrupted by dyspnea, caused by
sticky saliva allocated to radiotherapy. The earlier-mentioned
burning sensation of the eyeball was also reason to prema-
turely stop hyperthermia treatment, but this pain manifested
in only 1/6 treatments. No reason to prematurely stop treat-
ment was given for four patients (six treatments), probably
technical problems or patients discomfort was reason to stop
treatment. One patient fulfilled hyperthermia treatment time,
but developed cardiac arrhythmia that recovered spontan-
eously and did not recur.
One patient with a recurrent oropharyngeal carcinoma
experienced pain caused by a metal implant in the mandible
after the first hyperthermia treatment. A catheter was placed
close to the implant and a new hyperthermia plan was made
to reduce local power, which resulted in five complete hyper-
thermia sessions. No complaints during hyperthermia treat-
ments were seen in another patient with metal implants
within the CTV. The presence of dental fillings within the CTV
also appeared tolerable.
Toxicity due to irradiation was present in most patients.
Radiotherapy toxicity had a median score of grade 3, this
was caused by tube feeding (11 patients), radiation derma-
titis (Moist desquamation in areas other than skin folds and
creases, in 2 patients), pneumonitis (2 patients) and fibrosis
(1 patient).
Follow-up
The median follow-up time of this study was 13months
(range 2–107months). After three months, an overall
response rate of 59% was noted. Figure 3 provides MRI scans
of an example patient with a cT4N0M0 base of tongue car-
cinoma that was successfully treated. After three months,
complete response (CR) excluding the 3 patients with PORT
and partial response (PR) were seen in 46% and 7%, respect-
ively (Table 3). CR rates for locally-advanced and recurrent
HNC were 78% and 39%, respectively. The 2-year
Kaplan–Meier estimates of local control (LC) and overall sur-
vival (OS) were 40% and 44%, respectively. The 2-year rates
for patients with locally advanced disease were of 50% (LC)
and 67% (OS) and for re-irradiated patients 36% (LC) and
33% (OS). The 2-year rates for patients with PORT were of
100% (LC) and 67% (OS) and for no-PORT patients 32% (LC)
and 42% (OS). Kaplan Meier figures are added as supplemen-
tary files.
Discussion
In this study, we assessed the feasibility of hyperthermia
using the HYPERcollar in HNC. The mentioned 27 patients
showed good compliance since 87% of the treatments were
completed. To ensure a 60-min hyperthermia treatment,
treatment time was increased to 75min, which did not
reduce the completion rate and the power applied was even
higher, probably due to a learning curve and the implemen-
tation of improved positioning and complaint-adaptive
hyperthermia [22]. The improvements are also reflected in
the SARest, which increased from 60.7W/kg (60-min group) to
81.8W/kg (75-min group). Unfortunately, no improvement in
measured median and maximum temperature were
observed, which we allocate to a change in the catheter
positioning protocol. Initially, we measured at locations of
high-predicted SAR aimed at validating heating feasibility by
measuring the highest temperature, but later we measured
at low SAR locations to monitor and improve the lowest tar-
get temperatures. Note that only 8/27 patients received inva-
sive thermometry, while dosimetry by SARest was performed
in all patients and, although affected by waterbolus shape
differences, provides a 3D assessment. We conclude that a
higher time-temperature hyperthermia dose was achieved
since at least equal, but probably higher temperatures, were
obtained accompanied by an increased treatment time.
The quality of hyperthermia can be expressed in median
temperature (T50), lowest temperature (T90) or thermal dose
(CEM43T90) [27]. In our study the median measured T50 was
39 C in the 16/27 patients were invasive thermometry was
available. Note that T90 and CEM43T90 were not assessed
Table 2. Thermometry, toxicity and response data of included patients.
Parameter
HT treatments (n) 119
Incomplete (n (%)) 15 (13)
Applied power (Watt) (median (range)) 543 (120–1007)
60minute hyperthermia (median (range)) 464 (120–910)
75minute hyperthermia (median (range)) 595 (171–1007)
Estimated SAR (Watt/kg) (median (range)) 72.6 (12.0–181.0)
60minute hyperthermia (median (range)) 60.7 (12.0–181.0)
75minute hyperthermia (median (range)) 81.8 (27.9–158.5)
Maximum measured target temperature per patient
Total group (median (range)) 40.7 (38.1–42.3)
60minute hyperthermia (median (range)) 40.8 (40.0–42.3)
75minute hyperthermia (median (range)) 39.4 (38.1–40.8)
Median measured temperature per patient (T50)
Total group (median (range)) 38.8 (37.8–39.3)
60minute hyperthermia (median (range)) 39.0 (37.8–39.3)
75minute hyperthermia (median (range)) 38.2 (37.9–38.5)
Maximum measured temperature per tumor group
Head central (median (range)) 39.0 (38.1–40.0)
Head caudal (median (range)) 40.8 (40.7–42.3)
Neck (median) 40.6a
Tracheostomia (n (%)) 2 (7)
Metal implants in CTV (n (%)) 2 (7)
Dental fillings in CTV (n (%)) 3 (11)
Catheters interstitial (n (%)) 16 (59)
Response (%) 59
PR (n (%)) 2 (7)
CR (n (%)) 14 (52)
a1 patient with measured temperatures in the tumor.
CR: complete response; CTV: clinical target volume; HT: hyperthermia; PR: par-
tial response; SAR: specific absorption rate.
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since reliable estimates of the lowest achieved temperature
(T90), and hence lowest thermal dose (CEM43T90), in the tar-
get region requires over 10 probes, which was impossible
based on the few probes used in this study. In addition, tem-
peratures only served to verify our treatment approach since
using accurate simulations are being used for 3D dosimetry.
All temperatures were measured in tumor indicative normal
tissue locations and predominantly in patients with low
TC25% since invasive thermometry was mandatory. Also note
that, although most clinical trials are aimed at achieving
hyperthermia at 43 C in the tumor, in reality the measured
temperatures are much lower [28]. Intratumoral T50/T90 tem-
peratures of major successful multi-center phase III trials
were on average 40.3 C/39.2 C [29] and 39.4–40.9 C/
38.3–39.9 C [30,31]. Note that these studies reported meas-
ured temperatures at the cervix entrance or in poorly per-
fused tumor regions; hence the highest temperature in the
tumor is measured. Although the absence of 3D temperature
data hampers a true comparison, we believe that the tem-
perature levels obtained already were very close to those
reported in literature in the large target volumes treated
(median CTV size 63.5ml).
Combining our simulation and measurement data, we
observe a tremendous thermoregulatory response in the
head and neck: delivery of power in one case even beyond
1 kW and SARest levels beyond 80W/kg led to temperatures
below 43 C, i.e., the maximum measured temperature was
42.3 C. Reflecting the fact that the HYPERcollar was initially
developed for heating of the larynx, maximum temperature
results indeed were higher in this region (39.0 C vs 40.8 C).
To further improve the median temperatures we recently
introduced the novel HYPERcollar3D into the clinic, which
theoretically will double the SAR delivered to the target
region [23], as shown to be required in this study.
Simulation studies showed that patients with a tracheos-
toma could be treated with the HYPERcollar, as long as
the tumor is not located caudally of the tracheostoma.
Figure 3. Example of complete response after combined hyperthermia and irradiation in a cT4N0M0 carcinoma of the base of tongue.
Table 3. Response and survival of included patients.
Response after 3 months (n (%)) 59
PR 2 (7)
CR 14 (52)
CR locally advanced HNC 7 (78)
CR recurrent HNC 7 (39)
CR PORT 3 (100)
CR no-PORT 11 (46)
1 year 2 year
LC (%)
Total 55 40
PORT (3 pts) 100 100
no-PORT (24 pts) 49 32
OS (%)
Total 59 44
PORT (3 pts) 100 67
no-PORT (24 pts) 54 42
Locally advanced HNC (9 pts) (%)
LC 75 50
OS 67 67
Recurrent HNC (18 pts) (%)
LC 45 36
OS 56 33
CR: complete response; LC: local control; OS: overall survival;
PR: partial response; PORT: post-operative radiotherapy.
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The technical feasibility was confirmed by treatment of 2
patients with a tracheostoma, without positioning problems
and side effects, and TC25% was sufficiently high (56.7 and
63.9 in these two patients).
Toxicity of deep hyperthermia treatment was mild (mainly
grade 1). Most toxicity was due to metal implants >1 cm,
which were not taken out and caused edema and pain.
Toxicity due to metal dental fillings was not observed.
Gradually we experienced that sticky saliva is a factor that
can hamper hyperthermia treatment, and therefore, we
evacuate saliva before treatment. Furthermore, adequate
treatment with pain medication, sometimes with additional
short-acting opioids just before hyperthermia, lengthened
duration of treatment and eased patient positioning.
This study’s primary objective was to assess feasibility of
deep H&N heating. Secondary, clinical response was eval-
uated and despite the limited follow-up, promising results
were noticed, as 59% of our patients showed complete or
partial response. The included patients were either re-irradi-
ated, or had locally advanced disease. Other hyperthermia
studies used a variety of superficial heating [14,15,32,33].
Datta et al. treated 32 patients with combined irradiation
and local hyperthermia, for at least 20min twice a week.
They obtained a response in 63–76% for locally advanced
HNC [14]. Valdagni et al. treated metastatic lymph nodes in
stage IV HNC patients, and this randomized trial showed an
increase in 5 year nodal control of the hyperthermia and
irradiation group, compared to irradiation alone (69% versus
24%) [33]. The study of Hua et al. used nasopharyngeal cavity
hyperthermia added to irradiation and chemotherapy for
nasopharyngeal cancer. They showed improved 5 year local
control for the hyperthermia group (91% versus 79%) [32,34].
Huilgol et al. showed improved complete response (79%
versus 42%) and increased median survival time (241 vs
145 days) for the patients treated with irradiation combined
with hyperthermia, compared to irradiation alone [15].
A limitation of our study is the small sample size, the het-
erogeneous group, the short median follow-up time and the
retrospective nature. Randomized trials with long-term fol-
low-up are needed to assess the exact benefit of adding
deep hyperthermia to irradiation. The strength of our study
is that our data show that a variety of anatomic sites can be
treated using the HYPERcollar, without major toxicity.
Hyperthermia causes a plethora of effects like the direct
cytotoxic effects in hypoxic regions, inhibition of DNA double
strand break repair and reversion of hypoxia by increased
blood flow in tumors [35]. The latter effect is specifically
interesting in HNC scenarios since these tumors harbour hyp-
oxic areas and randomized trials for dose-escalation to over-
come this are ongoing [36]. Our data in recurrent disease
show that heating deeply located tumors in the head and
neck region is feasible, which allows to exploit the specific
benefits in a much larger group of patients then before.
Future studies may investigate the use of hyperthermia as
adjuvant to also primary irradiation, e.g., in patients above 70
that generally do not benefit from chemotherapy [37] and
HPV positive cases, where chemotherapy might be replaced
by hyperthermia. The biological evidence and already exist-
ing clinical data [13], supplemented with our data on
hyperthermia feasibility in deeply located HNC, are a strong
rationale for designing new clinical studies for exploitation of
the large opportunities that this new technology provides in
larger groups of patients.
Conclusion
This study shows that deep hyperthermia using the
HYPERcollar is safe and feasible since no severe (>Grade II)
hyperthermia-related toxicity was observed. In addition, deep
hyperthermia using the HYPERcollar might be effective since
46% of patients without PORT showed complete or partial
response. The high simulated SAR values combined with the
measured temperatures at the target regions periphery indicate
that adequate deep hyperthermia is achievable in a proportion
of patients, but that improved technology is needed to achieve
good heating in all patients. Given the promising dosimetric
and early clinical results, the addition of deep H&N hyperther-
mia to radiotherapy is now part of the standard of care in our
institution for patients with recurrent HNC and a study on
hyperthermia for primary treatment of HNC is in preparation.
Acknowledgments
We thank all participating patients, Cobi van der Zee and Netteke van
Holthe for their work.
Disclosure statement
MMP has financial interest in Sensius BV. No potential conflict of interest
was reported by the authors.
Funding
This study on irradiation combined with deep hyperthermia treatment
using the HYPERcollar was supported by research funding from KWF
Kankerbestrijding/Dutch Cancer Society, Technology Foundation STW,
the Maurits and Anna de Kock Foundation, Stichting Bevorderings
Volkskracht Rotterdam, the Nijbakker-Mora Stichting and the Dutch
National Aerospace Laboratory.
References
[1] Pignon JP, Le Maitre A, Maillard E, et al. Meta-analysis of chemo-
therapy in head and neck cancer (MACH-NC): an update on 93
randomised trials and 17,346 patients. Radiother Oncol.
2009;92:4–14.
[2] Magrini SM, Buglione M, Corvo R, et al. Cetuximab and radiother-
apy versus cisplatin and radiotherapy for locally advanced head
and neck cancer: a randomized phase II trial. J Clin Oncol.
2016;34:427–435.
[3] Roh KW, Jang JS, Kim MS, et al. Fractionated stereotactic
radiotherapy as reirradiation for locally recurrent head and neck
cancer. Int J Radiat Oncol Biol Phys. 2009;74:1348–1355.
[4] Yamazaki H, Kodani N, Ogita M, et al. Reirradiation of head and
neck cancer focusing on hypofractionated stereotactic body radi-
ation therapy. Radiat Oncol. 2011;6:98.
[5] Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG
9610, a multi-institutional trial of reirradiation and chemotherapy
for unresectable recurrent squamous cell carcinoma of the head
and neck. Head Neck. 2008;30:281–288.
[6] Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose
paclitaxel and cisplatin in combination with split-course
1000 G. M. VERDUIJN ET AL.
concomitant twice-daily reirradiation in recurrent squamous cell
carcinoma of the head and neck: results of Radiation Therapy
Oncology Group Protocol 9911. J Clin Oncol. 2007;25:4800–4805.
[7] Vargo JA, Ward MC, Caudell JJ, et al. A multi-institutional com-
parison of SBRT and IMRT for definitive reirradiation of recurrent
or second primary head and neck cancer. Int J Radiat Oncol Biol
Phys. 2018;100(3):595–605.
[8] Kampinga HH. Cell biological effects of hyperthermia alone or
combined with radiation or drugs: a short introduction to new-
comers in the field. Int J Hyperthermia. 2006;22:191–196.
[9] Amichetti M, Romano M, Busana L, et al. Hyperfractionated radi-
ation in combination with local hyperthermia in the treatment of
advanced squamous cell carcinoma of the head and neck:
a phase I-II study. Radiother Oncol. 1997;45:155–158.
[10] Sugahara T, van der Zee J, Kampinga HH, et al. Kadota Fund
International Forum 2004. Application of thermal stress for the
improvement of health, 15-18 June 2004, Awaji Yumebutai
International Conference Center, Awaji Island, Hyogo, Japan. Final
report. Int J Hyperthermia. 2008;24:123–140.
[11] Jones EL, Oleson JR, Prosnitz LR, et al. Randomized trial of hyper-
thermia and radiation for superficial tumors. J Clin Oncol.
2005;23:3079–3085.
[12] Franckena M. Review of radiotherapy and hyperthermia in pri-
mary cervical cancer. Int J Hyperthermia. 2012;28:543–548.
[13] Datta NR, Rogers S, Ordonez SG, et al. Hyperthermia and radio-
therapy in the management of head and neck cancers: a system-
atic review and meta-analysis. Int J Hyperthermia. 2016;32:31–40.
[14] Datta NR, Bose AK, Kapoor HK, et al. Head and neck cancers: results
of thermoradiotherapy versus radiotherapy. Int J Hyperthermia.
1990;6:479–486.
[15] Huilgol NG, Gupta S, Sridhar CR. Hyperthermia with radiation in
the treatment of locally advanced head and neck cancer: a report
of randomized trial. J Cancer Res Ther. 2010;6:492–496.
[16] Horsman MR, Overgaard J. Hyperthermia: a potent enhancer of
radiotherapy. Clin Oncol (R Coll Radiol). 2007;19:418–426.
[17] Paulides MM, Verduijn GM, Van Holthe N. Status quo and direc-
tions in deep head and neck hyperthermia. Radiat Oncol.
2016;11:21.
[18] Bonomo P, Cipressi S, Iermano C, et al. Salvage stereotactic re-
irradiation with CyberKnife for locally recurrent head and neck
cancer: a single center experience. Tumori. 2014;100:278–283.
[19] Cengiz M, Ozyigit G, Yazici G, et al. Salvage reirradiaton with
stereotactic body radiotherapy for locally recurrent head-and-
neck tumors. Int J Radiat Oncol Biol Phys. 2011;81:104–109.
[20] Paulides MM, Bakker JF, Linthorst M, et al. The clinical feasibility
of deep hyperthermia treatment in the head and neck: new chal-
lenges for positioning and temperature measurement. Phys Med
Biol. 2010;55:2465–2480.
[21] Verhaart RF, Fortunati V, Verduijn GM, et al. CT-based patient
modeling for head and neck hyperthermia treatment planning:
manual versus automatic normal-tissue-segmentation. Radiother
Oncol. 2014;111:158–163.
[22] Rijnen Z, Bakker JF, Canters RA, et al. Clinical integration of soft-
ware tool VEDO for adaptive and quantitative application of
phased array hyperthermia in the head and neck. Int J
Hyperthermia. 2013;29:181–193.
[23] Togni P, Rijnen Z, Numan WCM, et al. Electromagnetic redesign
of the HYPERcollar applicator: toward improved deep local head-
and-neck hyperthermia. Phys Med Biol. 2013;58:5997–6009.
[24] Franckena M, Fatehi D, de Bruijne M, et al. Hyperthermia dose-
effect relationship in 420 patients with cervical cancer treated
with combined radiotherapy and hyperthermia. Eur J Cancer.
2009;45:1969–1978.
[25] US Department of Health and Human Services; National Institutes
of Health; National Cancer Institute [Internet]. Common
Terminology Criteria for Adverse Events (CTCAE); Version 4.03
2010 June 14 [cited 2013 July]; Available from: http://evs.nci.nih.
gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.
pdf
[26] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evalu-
ation criteria in solid tumours: revised RECIST guideline (version
1.1). Eur J Cancer. 2009;45:228–247.
[27] Thrall D, Dewhirst M, Jones E, et al. A clinically proven, prospective,
thermal dose descriptor exists. Clin Cancer Res. 2006;12:1944–1945.
[28] van Rhoon GC. Is CEM43 still a relevant thermal dose parameter
for hyperthermia treatment monitoring? Int J Hyperthermia.
2016;32:50–62.
[29] Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy
alone or with regional hyperthermia for localised high-risk soft-
tissue sarcoma: a randomised phase 3 multicentre study. Lancet
Oncol. 2010;11:561–570.
[30] van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, et al.
Comparison of radiotherapy alone with radiotherapy plus hyper-
thermia in locally advanced pelvic tumours: a prospective, rando-
mised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet.
2000;355:1119–1125.
[31] Fatehi D, van der Zee J, Notenboom A, et al. Comparison of intra-
tumor and intraluminal temperatures during locoregional deep
hyperthermia of pelvic tumors. Strahlenther Onkol. 2007;183:
479–486.
[32] Hua Y, Ma S, Fu Z, et al. Intracavity hyperthermia in nasopharyn-
geal cancer: a phase III clinical study. Int J Hyperthermia.
2011;27:180–186.
[33] Valdagni R, Amichetti M. Report of long-term follow-up in a
randomized trial comparing radiation therapy and radiation ther-
apy plus hyperthermia to metastatic lymph nodes in stage IV
head and neck patients. Int J Radiat Oncol Biol Phys.
1994;28:163–169.
[34] Paulides MM, Van Rhoon GC. Towards developing effective hyper-
thermia treatment for tumours in the nasopharyngeal region.
Int J Hyperthermia. 2011;27:523–525.
[35] van den Tempel N, Odijk H, van Holthe N, et al. Heat-induced
BRCA2 degradation in human tumours provides rationale for
hyperthermia-PARP-inhibitor combination therapies. Int J
Hyperthermia. 2017;1–8. doi:10.1080/02656736.2017.1355487.
[36] Welz S, Monnich D, Pfannenberg C, et al. Prognostic value of
dynamic hypoxia PET in head and neck cancer: results from a
planned interim analysis of a randomized phase II hypoxia-image
guided dose escalation trial. Radiother Oncol. 2017;124:526–532.
[37] Pignon JP, Le Maitre A, Maillard E, et al. Meta-analysis of chemo-
therapy in head and neck cancer (MACH-NC): an update on 93
randomised trials and 17,346 patients. Radiother Oncol.
2009;92:4–14.
INTERNATIONAL JOURNAL OF HYPERTHERMIA 1001
